Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2018 Oct 8;13(10):1463-1470.
doi: 10.2215/CJN.00380118. Epub 2018 Sep 20.

Effect of Treatment of Metabolic Acidosis on Vascular Endothelial Function in Patients with CKD: A Pilot Randomized Cross-Over Study

Affiliations
Randomized Controlled Trial

Effect of Treatment of Metabolic Acidosis on Vascular Endothelial Function in Patients with CKD: A Pilot Randomized Cross-Over Study

Jessica Kendrick et al. Clin J Am Soc Nephrol. .

Abstract

Background and objectives: We examined the effect of alkali replacement for metabolic acidosis on vascular endothelial function in patients with CKD.

Methods: We performed a pilot, prospective, open-label 14-week crossover study examining the effect of oral sodium bicarbonate treatment on vascular function in 20 patients with an eGFR of 15-44 ml/min per 1.73 m2 with low serum bicarbonate levels (16-21 mEq/L). Each period was 6 weeks in duration with a 2-week washout period in between. Patients were treated to goal serum bicarbonate of ≥23 mEq/L. The primary end point was change in brachial artery flow-mediated dilation (FMD) between treatment and control conditions. Secondary end points included changes in markers of inflammation, bone turnover, mineral metabolism, and calcification.

Results: Eighteen patients completed the study and were included in the primary efficacy analysis. The mean (SD) age and eGFR were 59 (12) years and 26 (8) ml/min per 1.73 m2, respectively. Serum bicarbonate increased significantly with sodium bicarbonate treatment (+2.7±2.9 mEq/L, P≤0.001), whereas there was no change in bicarbonate levels in the control group. FMD significantly improved after sodium bicarbonate therapy (mean±SD, FMD baseline: 4.1%±4.1%; 6 weeks: 5.2%±2.9%; P=0.04) There was no significant change in FMD in the control group (mean±SD, FMD baseline: 4.6%±3.1%; 6 weeks: 4.1%±3.4%; P=0.20). Compared with control, sodium bicarbonate treatment resulted in a significant increase in FMD (mean, 1.8%; 95% confidence interval, 0.3 to 3.3; P=0.02). There was no significant change in bone markers or serum calcification propensity with treatment. Serum phosphorus and intact fibroblast growth factor 23 increased significantly during treatment.

Conclusions: Treatment of metabolic acidosis with sodium bicarbonate significantly improved vascular endothelial function in patients with stages 3b and 4 CKD.

Keywords: Alkalies; Bicarbonates; Bone Remodeling; Brachial Artery; Calcification, Physiologic; Control Groups; Cross-Over Studies; Dilatation; Fibroblast Growth Factors; Goals; Inflammation; Minerals; Phosphorus; Phosphorus, Dietary; Pilot Projects; Prospective Studies; Renal Insufficiency, Chronic; Sodium Bicarbonate; acidosis; chronic kidney disease; chronic metabolic acidosis; fibroblast growth factor 23; glomerular filtration rate; vascular disease.

PubMed Disclaimer

Figures

None
Graphical abstract
Figure 1.
Figure 1.
Study design.
Figure 2.
Figure 2.
Percent flow-mediated dilation at baseline and 6 weeks after sodium bicarbonate administration or control. FMD, flow-mediated dilation.

Comment in

References

    1. Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH: Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 164: 659–663, 2004 - PubMed
    1. Garnier AS, Briet M: Arterial stiffness and chronic kidney disease. Pulse (Basel) 3: 229–241, 2016 - PMC - PubMed
    1. Thambyrajah J, Landray MJ, McGlynn FJ, Jones HJ, Wheeler DC, Townend JN: Abnormalities of endothelial function in patients with predialysis renal failure. Heart 83: 205–209, 2000 - PMC - PubMed
    1. Yilmaz MI, Saglam M, Caglar K, Cakir E, Sonmez A, Ozgurtas T, Aydin A, Eyileten T, Ozcan O, Acikel C, Tasar M, Genctoy G, Erbil K, Vural A, Zoccali C: The determinants of endothelial dysfunction in CKD: Oxidative stress and asymmetric dimethylarginine. Am J Kidney Dis 47: 42–50, 2006 - PubMed
    1. Wang MC, Tsai WC, Chen JY, Huang JJ: Stepwise increase in arterial stiffness corresponding with the stages of chronic kidney disease. Am J Kidney Dis 45: 494–501, 2005 - PubMed

Publication types

Substances